IanFrankMD

Infectious Disease • Philadelphia, PA

HIV/AIDS Medicine

Professor, Medicine, Perelman School of Medicine

Join to view full profile

Dr. Frank is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Frank's full profile

Already have an account?

Office
3400 Spruce St
Philadelphia, PA 19104
Phone+1 215-662-6932

Fax+1 215-662-7899

Education & Training

Geisel School of Medicine at DartmouthClass of 2012
University of Pennsylvania Health SystemFellowship, Infectious Disease, 1984 - 1989
Graduate HospitalResidency, Internal Medicine, 1981 - 1983
St. Joseph Medical CenterInternship, Internal Medicine, 1980 - 1981

Certifications & Licensure

PA State Medical License 1981 - 2024
ME State Medical License Active through 1996
TX State Medical License 1981 - 1981
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Philadelphia Magazine Castle Connolly, 2004-2014
America's Top Doctors Castle Connolly, 2002-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients
Completed
Phase 1
Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV Start of enrollment: 2001 Feb 01
Completed
Phase 1, Phase 2
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection Start of enrollment: 2014 Apr 28
Completed
Phase 2
Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults Start of enrollment: 2018 Mar 16
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.
Dean Follmann, Xiaowei Wang, Lindsey R Baden, Hana M El Sahly, Brandon Essink
Open Forum Infectious Diseases. 2024-12-01
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, Monde Muyoyeta, Allan C deCamp
The Journal of Infectious Diseases. 2024-08-16
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected ad...
Ian Frank, Shuying S Li, Nicole Grunenberg, Edgar T Overton, Samuel T Robinson
The Lancet. HIV. 2024-05-01

Journal Articles

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
Matthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine

Press Mentions

UMass Chan Scientist Shan Lu Reports on Effectiveness of DNA Vaccine to Prevent HIVAugust 29th, 2024
Pro-Vaccine Study in ‘Science’ Linked to Pharmaceutical IndustryOctober 21st, 2021
Dogs Can Sniff Out COVID-19 CasesApril 18th, 2021
Join now to see all